Eventide Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Eventide Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.1M	Hold	1,297,893	–	–	0.33%	103
2025 Q4	$24.6M	Buy	+1,297,893	New	+$18.6M	0.38%	91
2022 Q3	–	Sell	-1,154,000	Closed	-$14.6M	–	148
2022 Q2	$14.6M	Sell	1,154,000 -716,000	-38%	-$8.12M	0.31%	82
2022 Q1	$26.2M	Hold	1,870,000	–	–	0.41%	74
2021 Q4	$54.1M	Buy	1,870,000 +670,000	+56%	+$20.3M	0.69%	45
2021 Q3	$36M	Hold	1,200,000	–	–	0.47%	68
2021 Q2	$31.8M	Hold	1,200,000	–	–	0.43%	71
2021 Q1	$37.3M	Buy	1,200,000 +150,000	+14%	+$5.68M	0.55%	64
2020 Q4	$34.5M	Buy	1,050,000 +552,260	+111%	+$18.3M	0.53%	61
2020 Q3	$17.4M	Buy	+497,740	New	+$12.5M	0.34%	81

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Eventide Asset Management's NRIX Position: Q1 2026 in Review

Eventide Asset Management held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 1,297,893 shares worth $20.1M. The position accounts for 0.33% of the portfolio, ranked #103.

Eventide Asset Management first reported a position in NRIX in Q3 2020 and has held it in 10 quarters since. The position peaked at $54.1M in Q4 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Eventide Asset Management held 1,297,893 shares of Nurix Therapeutics worth $20.1M as of Q1 2026.
Eventide Asset Management left its Nurix Therapeutics share count unchanged in Q1 2026.
Nurix Therapeutics made up 0.33% of Eventide Asset Management's portfolio in Q1 2026, its #103 holding.
Eventide Asset Management first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 10 quarters since.
Eventide Asset Management's Nurix Therapeutics position peaked at $54.1M in Q4 2021.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.